These two are the same kind of machine. Both push fine needles into the skin and release radiofrequency - electrical energy that turns into heat - from the needle tips. Both use insulated needles, meaning the shaft is coated so the heat is delivered at depth rather than at the surface. The real differences are in the numbers, and in what has been published.
Genius is Lutronic's, and its hardware is described in more detail on paper. Its FDA summary states 49 needles in a 7 by 7 grid, each 200 microns across, on a 10 by 10 mm tip, running at 460 kHz, with depth set between 0.5 and 3.5 mm. A 2026 update lists tips of 49, 16, 14 or 25 needles and a maximum depth of 4 mm. Morpheus8 runs at 1 MHz with tips of 12, 24 and 40 pins, and its operator manual gives depths from a fixed 0.5 mm resurfacing tip up to 7 mm on the largest tips.
Here is the point most comparisons miss: almost none of the research people are shown belongs to either machine. A PubMed search for Morpheus8 returns 16 records and no randomised controlled trial. One published study names Genius. The studies that built the case for radiofrequency microneedling ran on a scattered set of other devices - Lumenis Legend Pro, Pollogen Voluderm, Jeisys and Lutronic units, and several machines the papers do not name at all. The evidence belongs to the class, not to a badge.
49 needles in a 7 by 7 grid, 200 microns across, on a 10 by 10 mm tip.
Tips of 12, 24 and 40 pins, coated except for the last 0.5 mm.
Bipolar means the current stays between electrodes inside the tip rather than travelling through the body to a return pad. Its FDA summary says the therapeutic effect comes from "the uninsulated portion of the needles" - the shaft is coated and the exposed tip does the work.
The operator manual describes needles coated with insulating material except for the distal 0.5 mm.
The 2026 update (K253484, June 2026) adds one word: electrocoagulation/contraction and hemostasis. Wrinkles, acne scars and laxity appear in neither version, and neither carries a skin type restriction.
Above 62 millijoules per pin, Morpheus8 is limited on-label to Fitzpatrick skin types I to IV.
Published protocols in this field cluster at three sessions, three to eight weeks apart.
Published trials of this class most often used three.
Lutronic markets Genius on real-time impedance feedback - the device reading the electrical resistance of the tissue as the needles go in, and adjusting energy to suit. It is a genuinely appealing idea, because it is meant to confirm that the needles are where the operator believes they are.
The FDA summary for Genius does not describe an automated feedback system. So this is the manufacturer describing its own product, not something confirmed in the regulatory paperwork. If it matters to you, ask the clinic to show you what the screen displays during treatment and what changes when the reading changes.
For context, feedback is documented in the FDA paperwork of two other devices in this category: Candela's original Profound system, whose summary describes temperature sensors giving real-time tissue temperature between 65 and 75 degrees Celsius, and Candela's newer Matrix Pro applicator, described with real-time impedance monitoring. Neither of those is Genius, and neither is Morpheus8.
The best-evidenced use of this class is atrophic acne scars - the sunken, pitted kind. A systematic review of 16 studies covering 481 patients, including 6 randomised trials, concluded the treatment is "likely an effective treatment for acne scarring" as a stand-alone - note the hedge. A 2026 split-face trial in which the assessors did not know which side had which treatment found no significant difference between radiofrequency microneedling and fractional CO2 laser on acne scar scores, with shorter redness, pain, swelling and scabbing and fewer episodes of darkened skin afterwards on the radiofrequency side.
Six months is where the published evidence stops. The longest properly measured follow-up in controlled studies is six months after the last treatment. Clinic copy claiming one to three years has no published source.
Only one published study names Genius itself: 23 older patients treated once on the forearm for senile purpura, where collagen, elastic fibre and epidermal thickness measurements "tended to improve" but did not reach statistical significance, and 65 per cent were very satisfied. That is not a facial study, and it is one small single-arm trial.
Neither device, in other words, carries meaningful trial evidence of its own for the things people buy it for. The thing being sold here is a feedback system that the regulatory record does not describe. Ask to see what the screen does.
An analysis of the FDA's postmarket reporting database covering 2013 to 2025 found 114 reports containing 224 events for radiofrequency microneedling devices as a group, most often textural changes (56), pigment changes (41) and fat loss (26). That database is voluntary and has no denominator, so none of those counts can be turned into a chance that something happens to you - and a split-face study in 30 people that measured the fat layer under the chin by ultrasound found the dermis thickened while the fat layer did not change significantly.
If you get cold sores, say so when you book, not on the day. Antiviral medicine is started in advance, so it has to be prescribed beforehand. There is no published data on cold sore reactivation after radiofrequency microneedling specifically; the precaution is carried over from laser resurfacing, where reactivation is well documented.
Also disclose a pacemaker or implantable defibrillator, and any metal implant in or near the treatment area. These are labelled contraindications for radiofrequency devices generally. They are precautionary rather than tested, and your cardiology team - not a clinic - is the right source of advice.